Biotech Values

[iwfal]

The second stated reason for rejection—insufficient immunologic data—is surprising because GTC has stated that no one among the 200 or so individuals who have received ATryn in the various clinical trials has ever shown antibodies against the drug.

This sounds an awful lot like the scientific version of "Biotech animals just scare me. I can't tell you why, they just do." The EU version of the FDA ruling on the morning after pill.

Very sad day for patients.